Higher rates have been reported in patients treated with anti-CTLA4 antibodies compared to anti-PD1 for both diarrhea and colitis (30.2–35.4% vs. 12.1–13.7% and 5.7–9.1% vs. 0.7–1.6%, respectively) [41]. The gene discussed is CTLA4; the disease is colitis.